MedTrace Logo

Anti-CMV Cellular Immunity Quantification Using an IGRA Test in Kidney Transplant récipients and Hemodialysis Patients, Comparison to Control Patients

NCT03916497 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2020-09-04

No results posted yet for this study

Summary

Evaluation of anti-CMV T cellular immunity using an IGRA test (Quantiferon-CMV test) in kidney transplant recipients and hemodialysis patients, comparison to control patients.

Conditions

  • Quantiferon-CMV
  • Cytomegalovirus Infections
  • Kidney Transplant Infection
  • Hemodialysis

Interventions

DIAGNOSTIC_TEST

Quantiferon CMV

Evaluate and compare interferon gamma (IFNy) production by T CD8 cells exposed to CMV antigens in CMV seropositive kidney transplant recipients, hemodialysis and control patients

Sponsors & Collaborators

  • University Hospital, Grenoble

    lead OTHER

Principal Investigators

  • Lionel Rostaing · Centre Hospitalier Universitaire Grenoble-Alpes

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-30
Primary Completion
2019-07-30
Completion
2019-07-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03916497 on ClinicalTrials.gov